- Research Tracker
- Supplement safety
- Nicotinamide riboside and other NAD+ precursors
What public sources say about the safety of nicotinamide riboside and other NAD+ precursors: FDA adverse-event reports, NIH guidance on interactions with medicines, and the registered trials that test it.
Interactions and safety
NIH does not publish a fact sheet for this supplement. Ask a pharmacist or clinician to check it against any medicines you take.
FDA adverse-event reports (CAERS)
Matching rule: reports in the dietary-supplement category where a product marked "suspect" has a brand name containing “NICOTINAMIDE RIBOSIDE”, “NIAGEN”, “NMN”. Products that contain it without naming it are missed. Reports where it was only taken alongside the suspect product are not counted.
Combination products: 3 of the reports involve only products whose name lists another ingredient, such as calcium or a multivitamin. Their reactions may come from that other ingredient or from the tablet itself, so the reactions below count only the 40 reports where a product is named for nicotinamide riboside and other NAD+ precursors alone. This split is made from product names and can misfile some products. Most-reported products: Tru Niagen (12); Chromadex Tru Niagen (5); Tru Niagen Age Better (2); Ultra Nmn (2); Persona Nutrition Tru Niagen (2); Tru Niagen Pro Clinical Strength (2).
| Most reported reactions (single-ingredient products) | Reports |
|---|---|
| Hypersensitivity | 3 |
| Insomnia | 3 |
| Diarrhoea | 3 |
| Vomiting | 3 |
| Blood pressure increased | 3 |
| Nausea | 3 |
| Abdominal pain | 3 |
| Hepatic enzyme increased | 2 |
| Malaise | 2 |
| Abdominal tenderness | 2 |
| Abdominal pain upper | 2 |
| Atrial fibrillation | 2 |
Outcomes recorded in these reports (a report can have several): Other Serious or Important Medical Event (27), Other Serious Outcome (13), Visited Emergency Room (9), Hospitalization (5), Visited a Health Care Provider (5), Disability (4), Life Threatening (3), Other Outcome (1).
Source: openFDA food and supplement adverse events (CAERS), retrieved 2026-11-16.
Registered trials
25 trials in the non-drug evidence map test this class of supplement. Trials with posted results are listed first; each shows the condition it was registered for. A trial testing it in one condition says nothing about another.
- Nicotinamide Riboside in Systolic Heart Failure Completed Results posted
- Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Completed Results posted
- Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis Completed Results posted
- NR in Chemo-induced Peripheral Neuropathy Terminated Results posted
- Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid Completed
- Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome Completed
- The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders. Completed
- Senolytics to Improve Osteoporosis Therapy Completed
- A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease Completed
- N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease Completed
- NAD Supplementation and Vascular Health in PAD Completed
- Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome Completed
- The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. Active, not recruiting
- A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study Active, not recruiting
- Nicotinamide Riboside Supplementation in Chronic Kidney Disease Not yet recruiting
- Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD Active, not recruiting
- Nicotinamide Riboside for Diabetic Neuropathy Terminated
- Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients Recruiting
- Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Active, not recruiting
- The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease Recruiting